| Literature DB >> 28751833 |
Michele Massimo Gulizia1,2, Furio Colivicchi1, Gualtiero Ricciardi3, Simona Giampaoli3, Aldo Pietro Maggioni4, Maurizio Averna5, Maria Stella Graziani6, Ferruccio Ceriotti6, Alessandro Mugelli7, Francesco Rossi7, Gerardo Medea8, Damiano Parretti8, Maurizio Giuseppe Abrignani1, Marcello Arca5, Pasquale Perrone Filardi9, Francesco Perticone10, Alberico Catapano5, Raffaele Griffo11, Federico Nardi1, Carmine Riccio1, Andrea Di Lenarda1, Marino Scherillo1, Nicoletta Musacchio12, Antonio Vittorio Panno13, Giovanni Battista Zito14, Mauro Campanini15, Leonardo Bolognese16, Pompilio Massimo Faggiano17, Giuseppe Musumeci17, Enrico Pusineri18, Marcello Ciaccio6, Enzo Bonora19, Giorgio Cantelli Forti7, Maria Pia Ruggieri20, Claudio Cricelli8, Francesco Romeo9, Roberto Ferrari9, Attilio Maseri21.
Abstract
Atherosclerotic cardiovascular disease still represents the leading cause of death in Western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proved effective in improving clinical outcomes. This document focuses on the clinical management of hypercholesterolaemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors discuss in detail the role of hypercholesterolaemia in the genesis of atherosclerotic cardiovascular disease. In addition, the implications for high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analysed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been explored. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolaemia.Entities:
Keywords: Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care
Year: 2017 PMID: 28751833 PMCID: PMC5526476 DOI: 10.1093/eurheartj/sux029
Source DB: PubMed Journal: Eur Heart J Suppl ISSN: 1520-765X Impact factor: 1.803